Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P17
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.24% |
| Q3 2025 | -7.04% |
| Q2 2025 | 9.98% |
| Q1 2025 | -2.11% |
| Q4 2024 | 11.57% |
| Q3 2024 | -19.77% |
| Q2 2024 | -13.50% |
| Q1 2024 | 3.82% |
| Q4 2023 | -0.34% |
| Q3 2023 | -30.32% |
| Q2 2023 | 8.70% |
| Q1 2023 | 19.48% |
| Q4 2022 | 35.27% |
| Q3 2022 | -30.53% |
| Q2 2022 | 17.42% |
| Q1 2022 | -33.60% |
| Q4 2021 | 50.12% |
| Q3 2021 | -1.27% |
| Q2 2021 | 13.41% |
| Q1 2021 | -6.83% |
| Q4 2020 | 46.86% |
| Q3 2020 | 3.17% |
| Q2 2020 | 19.77% |
| Q1 2020 | -1.27% |
| Q4 2019 | 24.79% |
| Q3 2019 | 47.33% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |